CYCN Cyclerion Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CYCN

Price (delayed)

$3.17

Market cap

$8.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

$2.9M

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates ...

Highlights
The net income has surged by 103% since the previous quarter and by 100% year-on-year
Cyclerion Therapeutics's EPS has soared by 100% YoY and by 98% from the previous quarter
The equity has soared by 153% YoY but it has contracted by 12% from the previous quarter
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cyclerion.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of CYCN
Market
Shares outstanding
2.71M
Market cap
$8.59M
Enterprise value
$2.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$197,000
EBITDA
-$197,000
Free cash flow
-$16.9M
Per share
EPS
-$0.04
Free cash flow per share
-$6.78
Book value per share
$3.66
Revenue per share
$0
TBVPS
$4.56
Balance sheet
Total assets
$11.36M
Total liabilities
$1.44M
Debt
$0
Equity
$9.92M
Working capital
$4.57M
Liquidity
Debt to equity
0
Current ratio
4.17
Quick ratio
3.95
Net debt/EBITDA
28.91
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
1.2%
Return on equity
1.5%
Return on invested capital
-7%
Return on capital employed
-2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYCN stock price

How has the Cyclerion Therapeutics stock price performed over time
Intraday
0.63%
1 week
-6.76%
1 month
41.52%
1 year
6.38%
YTD
-5.37%
QTD
39.04%

Financial performance

How have Cyclerion Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.67M
Net income
$149,000
Gross margin
N/A
Net margin
N/A
The net income has surged by 103% since the previous quarter and by 100% year-on-year
The revenue has dropped by 100% year-on-year
The company's gross profit has shrunk by 100% YoY
The operating income has grown by 47% YoY but it has contracted by 6% from the previous quarter

Growth

What is Cyclerion Therapeutics's growth rate over time

Valuation

What is Cyclerion Therapeutics stock price valuation
P/E
N/A
P/B
0.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cyclerion Therapeutics's EPS has soared by 100% YoY and by 98% from the previous quarter
The equity has soared by 153% YoY but it has contracted by 12% from the previous quarter
The stock's price to book (P/B) is 53% less than its 5-year quarterly average of 1.9 and 10% less than its last 4 quarters average of 1.0
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Cyclerion Therapeutics business performance
CYCN's return on assets has surged by 103% since the previous quarter and by 101% year-on-year
The company's return on equity has surged by 102% QoQ and by 101% YoY
The return on invested capital has surged by 99% since the previous quarter

Dividends

What is CYCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYCN.

Financial health

How did Cyclerion Therapeutics financials performed over time
Cyclerion Therapeutics's total liabilities has plunged by 81% YoY and by 31% from the previous quarter
Cyclerion Therapeutics's total assets has decreased by 15% from the previous quarter
Cyclerion Therapeutics's debt is 100% less than its equity
The equity has soared by 153% YoY but it has contracted by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.